-
The EMA recommends by consensus the approval of HEPIZOVAC, the first vaccine against epizootic hemorrhagic disease.
-
A pioneer in the market and unique in its ability to prevent viremia caused by serotype 8 of the EHE virus in cattle
-
The vaccine is marketed in Spain and Portugal by Vetia Animal Health, a subsidiary specializing in animal health.
O Porriño, March 17, 2025 – The biotechnology group Zendal has just received a positive recommendation from the Committee for Veterinary Medicines (CVMP), belonging to the European Medicines Agency (EMA), for the granting of marketing authorization for HEPIZOVAC, a vaccine intended for the prevention of epizootic hemorrhagic disease (EHE) in cattle, caused by serotype 8 of the virus.
This consensus recommendation marks a fundamental milestone in the regulatory process of this vaccine, a pioneer in the market and unique in its ability to prevent viremia caused by serotype 8 of the EHE virus in cattle.
A key step forward in the fight against EHE
The epizootic hemorrhagic disease (EHE) virus, which affects domestic and wild ruminants, was first detected in southwest Spain in November 2022. Faced with the rapid spread of the disease, the Ministry of Agriculture, Fisheries and Food requested the biotechnology group based in O Porriño to prioritize the development of an effective solution.
As a result, in July 2024, the group received temporary authorization for use from the Spanish Agency for Medicines and Health Products (AEMPS) for the new vaccine, the first on the market.
Commitment to the livestock sector
The epizootic hemorrhagic disease continues to spread through Spain, France and other European countries, causing multiple economic losses in cattle farms, both for meat and milk, due to both direct mortality in animals and the symptoms associated with the disease and the sequelae in animals that have overcome the viremic phase of the disease.
HEPIZOVAC has proven its effectiveness for the active immunization of cattle against serotype 8 of the EHE virus, offering a key solution to protect cattle and mitigate the economic impact of the disease on the livestock sector in Europe.
Hepizovac is marketed in Spain and Portugal by Vetia Animal Health, a subsidiary of the Zendal group specializing in animal health.
About Zendal Group
Zendal is the corporate brand of the biotechnology group focused on the research, development, manufacturing, and marketing of human and animal vaccines and other high-value-added pharmaceutical products for the healthcare sector. It has three R&D centers and several biopharmaceutical production plants in its laboratories in O Porriño, León, Barcelona, and Paredes de Coura (Portugal).
